为肝细胞癌武装 GPC3 CAR T 细胞:多少才足够,下一步是什么?
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
FRONTIER PAPERS
Armouring GPC3 CAR T cells for hepatocellular carcinoma: how much is enough and what comes next?
IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity.
这些发现支持利用IL-18开发下一代细胞因子武装的CAR-NKT癌症免疫疗法。
CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation.
嵌合抗原受体(CAR)-T细胞疗法已经改变了肿瘤免疫治疗,在血液系统肿瘤中实现了持久的完全缓解。
rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors.
本研究为 NT-I7 联合 CAR-T 细胞治疗人类实体瘤提供了依据。
Disruption of TGF-β signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells.
我们的发现表明,要实现 NK 细胞针对 HCC 的有效功能,阻断 TGF-β 信号是必需的,对其他高表达 TGF-β 的恶性肿瘤可能也是如此。
Targeting Lin28 axis enhances glypican-3-CAR T cell efficacy against hepatic tumor initiating cell population.
我们的结果表明,抑制Lin28B可降低IDO1和PD-L1表达,并增强GPC3-CART细胞对HCC的免疫治疗潜力。
Integrated therapies for targeting the microenvironment of hepatocellular carcinoma.
肝细胞癌(HCC)微环境(MEs)由免疫和非免疫成分组成,这些成分驱动肿瘤进展和治疗耐药。
Integrated Imaging Probe and Bispecific Antibody Development Enables In Vivo Targeting of Glypican-3-Expressing Hepatocellular Carcinoma.
这些数据表明,使用源自小肽的 GPC3/CD3 TRAB 靶向 HCC 细胞,能够在体外和体内有效激活 T 细胞并诱导针对 GPC3+ HCC 肿瘤细胞的细胞毒性反应。
Derivation and Preclinical Characterization of CYT-303, a Novel NKp46-NK Cell Engager Targeting GPC3.
这些结果证明了 CYT-303 有潜力成为针对 HCC 的安全有效疗法。
Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC.
我们的发现表明,与靶向近膜表位相比,改变靶向 GPC3 远端表位的纳米抗体 CAR 的铰链区和跨膜结构域,可导致强健的 T 细胞信号传导,并诱导快速且持久地清除肝细胞癌(HCC)肿瘤。
MEMBER ACCOUNT
登录成功会直接打开下一页。